Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.08. | Stifel bestätigt Kaufempfehlung für Rapid Micro Biosystems und hält an Kursziel von 8 US-Dollar fest | 1 | Investing.com Deutsch | ||
13.08. | Stifel reiterates Buy rating on Rapid Micro Biosystems stock, maintains $8 target | 2 | Investing.com | ||
12.08. | Rapid Micro Biosystems reaffirms $32M revenue guidance for 2025 as recurring revenue climbs 15% | 1 | Seeking Alpha | ||
12.08. | Rapid Micro Biosystems secures $45 million term loan facility | 1 | Investing.com | ||
12.08. | Rapid Micro Biosystems GAAP EPS of -$0.27, revenue of $7.3M | 1 | Seeking Alpha | ||
12.08. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results | 591 | GlobeNewswire (Europe) | Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second... ► Artikel lesen | |
12.08. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc. | 573 | GlobeNewswire (Europe) | $20 million drawn down at closing, with access to up to an additional $25 million Strengthens Company's financial position and reinforces ability to achieve positive cash flow LEXINGTON, Mass.,... ► Artikel lesen | |
RAPID MICRO BIOSYSTEMS Aktie jetzt für 0€ handeln | |||||
12.08. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
11.08. | A Look Ahead: Rapid Micro Biosystems' Earnings Forecast | 2 | Benzinga.com | ||
31.07. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce Second Quarter 2025 Financial Results on August 12, 2025 | 2 | GlobeNewswire (USA) | ||
28.07. | Lake Street initiates Rapid Micro Biosystems stock with Buy rating on MQC growth | 6 | Investing.com | ||
28.07. | Automatisierte Qualitätskontrolle als Wachstumstreiber: Lake Street stuft Rapid Micro Biosystems mit "Buy" ein | 2 | Investing.com Deutsch | ||
17.06. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
13.06. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 167 | GlobeNewswire (Europe) | LEXINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation... ► Artikel lesen | |
27.05. | Rapid Micro Biosystems appoints new board member | 1 | Investing.com | ||
27.05. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors | 1 | GlobeNewswire (USA) | ||
23.05. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
09.05. | RAPID MICRO BIOSYSTEMS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
09.05. | Rapid Micro Biosystems reports Q1 results | 2 | Seeking Alpha | ||
09.05. | RAPID MICRO BIOSYSTEMS, INC. Q1 Loss Decreases, Beats Estimates | 1 | RTTNews |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,590 | +2,22 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 58,58 | +0,72 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
EVOTEC | 6,072 | +1,20 % | Die Blaupause für KI-Medikamentenentwicklung: So nutzen Evotec, NetraMark Holdings und BioNTech die neuen Möglichkeiten | Die Pharmabranche befindet sich mitten in einer Revolution. Künstliche Intelligenz verkürzt die Wirkstoffentwicklung von Jahren auf Monate und steigert die Trefferquote dramatisch. Datengetriebene Prognosen... ► Artikel lesen | |
BIONTECH | 87,45 | +0,23 % | Paukenschlag beim Übernahmekandidaten! 100 %-Aktie BioNxt Solutions lässt BioNTech und Co. hinter sich! | Die Aktie von BioNxt ist endlich angesprungen. Anfang Juli hatten wir zuletzt auf die Chancen des kanadisch-deutschen Biowissenschaftsunternehmens hingewiesen. Seitdem ist die Aktie um fast 100 % gestiegen... ► Artikel lesen | |
IMMUNOVANT | 14,690 | -0,88 % | Immunovant, Inc. - 8-K, Current Report | ||
ARS PHARMACEUTICALS | 11,610 | -9,72 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
LENZ THERAPEUTICS | 38,630 | +1,13 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 23,710 | -2,91 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
AVIDITY BIOSCIENCES | 46,540 | -4,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
ARRIVENT BIOPHARMA | 19,120 | -0,52 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial Results | Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient... ► Artikel lesen | |
RAPPORT THERAPEUTICS | 17,630 | +4,94 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS)... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,690 | -3,60 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
ADMA BIOLOGICS | 17,255 | -0,72 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
DYNE THERAPEUTICS | 13,480 | -1,96 % | Dyne Therapeutics stock rises after Raymond James upgrade to Strong Buy | ||
ARCELLX | 69,43 | -1,17 % | Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial |